For the latest ecancer COVID-19 resources, click on this link

Breast

Prostate & urology

Lung & pleura

Colorectal & gastro

Melanoma & skin

Head & neck

Ovary & gynaecology

+ -

Circulating tumour cells

ECCO 15 - ESMO 34

20 - 24 Sep 2009

Published: 3 Nov 2009

Views: 12513

Rating:

Save

Anieta Sieuwerts - Erasmus University Rotterdam

Discusses the research presented on circulating tumour cells at ECCO 15 - ESMO 34, Berlin 2009.

Categories:
Diagnostics

Related Videos

Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or local...

Prof Thomas Powles - Queen Mary University of London, London, UK

Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or locally advanced urothelial carcinoma (mUC) and FGFRa ( Prof Thomas Powles - Queen Mary University of London, London, UK )

Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and dexamethaso...

Dr Enrique Ocio - Marqués de Valdecilla University Hospital, Santander, Spain

Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and dexamethasone combined therapy for NDMM ( Dr Enrique Ocio - Marqués de Valdecilla University Hospital, Santander, Spain )

Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or car...

Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA

Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in RRMM patients ( Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA )

Should every transplant eligible NDMM patient receive a transplant?

Prof Morie Gertz - Mayo Clinic, Rochester, USA

Should every transplant eligible NDMM patient receive a transplant? ( Prof Morie Gertz - Mayo Clinic, Rochester, USA )

Vaccinations in myeloma patients including for COVID-19

Prof Heinz Ludwig - Wilhelminen Cancer Research Institute, Vienna, Austria

Vaccinations in myeloma patients including for COVID-19 ( Prof Heinz Ludwig - Wilhelminen Cancer Research Institute, Vienna, Austria )

Culture, Community and Communication in Advanced Disease in India

Dr Dwai Banerjee - Massachusetts Institute of Technology, Boston, USA

Culture, Community and Communication in Advanced Disease in India ( Dr Dwai Banerjee - Massachusetts Institute of Technology, Boston, USA )

The role of the medical oncologist in the holistic care of patients with cancer ...

Dr Frederic Ivan Ting - Chair, Clinical Consensus Committee of the Philippine So...

The role of the medical oncologist in the holistic care of patients with cancer in the Philippines ( Dr Frederic Ivan Ting - Chair, Clinical Consensus Committee of the Philippine Society of Medical Oncology (PSMO) )

Predicting survival in NSCLC patients with poor performance status in resource-c...

Dr Akhil Kapoor - Tata Memorial Hospital, Mumbai, India

Predicting survival in NSCLC patients with poor performance status in resource-constrained settings ( Dr Akhil Kapoor - Tata Memorial Hospital, Mumbai, India )

Part 3: How to test

PARP inhibition in the treatment of prostate cancer

Part 3: How to test ( PARP inhibition in the treatment of prostate cancer )

More from ecancer